<DOC>
	<DOCNO>NCT01241448</DOCNO>
	<brief_summary>LY2409021 evaluate possible treatment type 2 diabetes . This study design compare LY2409021 give alone give combination metformin placebo change hemoglobin A1c 24-week treatment period .</brief_summary>
	<brief_title>A Study LY2409021 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Have diagnosis Type 2 diabetes mellitus accord World Health Organization ( WHO ) diagnostic criterion Are woman childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause . Are male patient use reliable method birth control study 3 month last dose study medication . Are treat either diet exercise alone , diet exercise combination metformin . Metformin therapy must stable unchanged least 3 month prior screen dose least 1000 mg/day . Have HbA1c value 7.0 % 10.5 % , inclusive . Have body mass index ( BMI ) 25 45 kg/m2 , inclusive . In opinion investigator , capable willing : Perform selfmonitoring blood glucose Complete study diary require protocol Maintain consistent dietary , physical activity , sleep pattern throughout duration study Comply treatment regimen Have give write informed consent participate study accordance local regulation Ethical Review Board ( ERB ) govern study site . Have 1 episode severe hypoglycemia ( defined event patient require assistance another person actively administer carbohydrate , glucagon , resuscitative action ) within 6 month prior screen , current diagnosis hypoglycemia unawareness . Have two emergency room visit hospitalization due poor glucose control 6 month prior screen . Have gastrointestinal disease may significantly impact gastric empty motility undergone gastric bypass gastric banding surgery . Have previous diagnosis pancreatitis . Have New York Heart Association ( NYHA ) class II , III , IV symptoms heart failure Have history myocardial infarction , unstable angina , coronary revascularization procedure within 6 month screen . Have history supraventricular tachycardia , ventricular tachycardia , cardiac arrhythmia . Have history transient ischemic attack ( TIA ) stroke within 6 month screen . Have poorly control hypertension ( systolic blood pressure great equal 150 mm Hg diastolic blood pressure great equal 90 mm Hg ) determine mean three separate measurement . Show evidence labile blood pressure , include symptomatic postural hypotension . Have abnormality ECG would impact patient safety data interpretation . Show clinical sign symptom liver disease , liver function test ( LFTs ; aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) great 2.5 time upper limit normal ( ULN ) determine central laboratory screening . Have current previous diagnosis Gilbert 's disease . Have previous current diagnosis Hepatitis B C Have serum creatinine &gt; 2 mg/dL , patient treat metformin , serum creatinine ( creatinine clearance ) approve metformin product label respective country . Show evidence uncorrected hypothyroidism hyperthyroidism base clinical evaluation and/or abnormal thyroid stimulate hormone result determine central laboratory screening ; patient receive dosestable thyroid replacement therapy least 3 month prior screen allow participate study . Have abnormal laboratory value , opinion investigator , precludes patient participation study . Laboratory abnormality consistent type 2 diabetes mellitus eligibility criterion acceptable : example , abnormality blood glucose , hemoglobin A1C ( HbA1c ) , urinary glucose , urinary protein ( range trace 1+ dipstick ) . Have currently suspect treated malignancy , remission clinically significant malignancy ( basal squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year . Have personal family history pancreatic neoplasia . Have nonfasting triglyceride &gt; 600 mg/dL . Use use insulin GLP1 agonist ( 1 week within 3month period prior screen ) , oral antihyperglycemic medication ( OAM ) metformin within 3month period prior screen . Currently use intend use prescription overthecounter medication , include herbal supplement , promote weight loss regulate blood glucose . Have current chronic ( &gt; 2 week ) systemic glucocorticoid therapy ( exclude ocular topical , topical , inhaled preparation ) receive therapy within 8 week prior screen . Currently use hyperglycemiacausing agent , hypoglycemiacausing agent ( metformin ) , class II III antiarrythmic agent , agent reduce gastrointestinal motility , central nervous system stimulant ( exception caffeinated beverage ) , fibrates , niacin great equal 1 gm/day . Have average weekly alcohol intake exceed 2 unit per day male 1 unit per day female ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Currently use drug narrow therapeutic index ( example , digoxin , lithium , phenytoin , theophylline , warfarin ) . Currently use drug know prolong QT interval . Currently use intend use potent inhibitor CYP3A , include limited atazanavir , indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , ketoconazole , nefazodone , saquinavir , telithromycin . Have previously complete withdrawn study study investigate LY2409021 . Have know allergy LY2409021 relate compound . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product unapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Have condition alcohol abuse , drug abuse , psychiatric disorder may affect ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>